AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00717054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Study NCT00717054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
Study NCT00717054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
Study NCT03444727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Pre-treatment
Description: Topical application of ice prior to local anesthetic injection.
Study NCT03444727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room Temperature Water Pre-treatment
Description: Topical application of room-temperature water prior to local anesthetic injection.
Study NCT03588299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2599023 (DTX201)
Description: Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
Study NCT04473183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Collection
Description: Blood: Two tubes of blood (up to 10 ml each) will be drawn from participants and will be collected by experienced phlebotomists.~Nasal, oral, and rectal swabs: Nasal, oral, and rectal swabs are optional specimens that patients may be asked to donate. If prospective consent is provided, swabs will be self-collected by participants after receiving clear instructions from the team and collected in the dedicated container.~Saliva: Saliva is an optional specimen that patients may be asked to donate. If prospective consent is provided, whole saliva samples will be self-collected by participants using a pad placed between the cheek and gum for 2-5 minutes or collecting the saliva directly to a sterile container.
Study NCT04473183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Surveys
Description: Participants will be asked to fill out a brief online survey that will investigate symptoms consistent with SARS-CoV-2 infection in the past 3 months and the geographic location of the clinic(s) they work in (if a resident of a medical school) and their comorbidities related to SARS-CoV-2.
Study NCT01947452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment
Description: Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
Study NCT01947452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-Emotional Learning
Description: Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
Study NCT01764048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fix protocol
Description: Please see arm description
Study NCT01764048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medications following demand protocol
Description: Please see arm description
Study NCT03689647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm Swing Driven Assistive Apparatus
Description: The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
Study NCT00691886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine hydrochloride
Description: Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
Study NCT02870413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telelactation services
Description: Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
Study NCT04506307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study NCT03600623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
Study NCT03600623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine nab-Paclitaxel
Description: SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
Study NCT00674193 — intervention group
Intervention type: OTHER
Intervention: pharmacological study
Description: Correlative studies
Study NCT00674193 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02366728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unpulsed DCs
Description: Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
Study NCT02366728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td
Description: Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
Study NCT02366728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
Study NCT02366728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In-labeled DCs
Description: 111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
Study NCT02366728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
Study NCT02366728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
Study NCT02366728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
Study NCT01323621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
Description: inhalation powder
Study NCT01323621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 250mcg / salmeterol 50mcg
Description: inhalation powder
Study NCT01323621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-dummy placebo
Description: inhalation powder
Study NCT01323621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-dummy placebo
Description: inhalation powder
Study NCT01323621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol as needed
Description: inhalation powder
Study NCT01323621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol as needed
Description: inhalation powder
Study NCT00593801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta
Description: 250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
Study NCT00593801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta
Description: 250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
Study NCT02086851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Study NCT02086851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Study NCT02086851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Motivational Interviewing
Study NCT01636791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
Study NCT01636791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
Study NCT01636791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to work
Description: Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
Study NCT01493258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCOPE Intervention group
Description: The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
Study NCT01168739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
Study NCT01168739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
Study NCT04628299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser
Description: Sham Laser in plantar fascia
Study NCT04628299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Induction
Description: Myofascial Induction in plantar fascia
Study NCT00716053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLVR
Description: BLVR 20 mL
Study NCT00716053 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: BLVR
Description: BLVR 20 mL
Study NCT01472380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600 mg
Study NCT01472380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibric acid 105 mg
Description: fenofibric acid 105 mg
Study NCT04626817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic device (Biodex System 4)
Description: The measurement of muscle strength with isokinetic device
Study NCT04626817 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Isokinetic device (Biodex System 4)
Description: The measurement of muscle strength with isokinetic device
Study NCT03250832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
Study NCT03250832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.
Study NCT03250832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
Study NCT03250832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
Study NCT03250832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
Study NCT00705432 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b (PEG)
Description: Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
Study NCT00705432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG)
Description: Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
Study NCT00705432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
Study NCT00705432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
Study NCT00705432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
Study NCT00705432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
Study NCT04338828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Gas
Description: Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
Study NCT04338828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Supplemental Oxygen
Description: 2 L/min oxygen therapy
Study NCT00620568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained release tablets taken once daily for 14 days
Study NCT01750541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study NCT01750541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Study NCT00892619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using ILM forceps alone
Description: Using ILM forceps to initiate and complete ILM peel
Study NCT00892619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breaking and peeling with end-grasping forceps
Description: Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
Study NCT05497648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~* One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~* Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions.
Study NCT02233283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamp
Description: Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
Study NCT02233283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
Study NCT02233283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
Study NCT02233283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal
Description: Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
Study NCT02233283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric diet
Description: Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
Study NCT02233283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric diet
Description: Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
Study NCT03653221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard patients with VRNET
Description: In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
Study NCT03653221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard patients
Description: In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
Study NCT01881503 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBOC-201
Description: HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
Study NCT03859726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NIRS
Description: Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
Study NCT03859726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual microcirculation
Description: The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
Study NCT03427125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Active Drug
Study NCT03427125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Drug
Study NCT03427125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: Active control
Study NCT01288872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
Study NCT03654313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570
Study NCT03654313 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03654313 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part B Placebo
Description: Placebo
Study NCT00902954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: anastrozole 1 mg qd
Study NCT00902954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: anastrozole 1 mg qd
Study NCT00902954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: letrozole 2.5 mg qd